Multaq

Multaq is a brand name of dronedarone, approved by the FDA in the following formulation(s):

MULTAQ (dronedarone hydrochloride - tablet; oral)

• 
  Manufacturer: SANOFI AVENTIS US
  
  Approval date: July 1, 2009
  
  Strength(s): EQ 400MG BASE ^[RLD]

Has a generic version of Multaq been approved?

No. There is currently no therapeutically equivalent version of Multaq available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Multaq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them
  Patent 5,223,510
  Issued: June 29, 1993
  Inventor(s): Gubin; Jean & Chatelain; Pierre & Lucchetti; Jean & Rosseels; Gilbert & Inion; Henri
  Assignee(s): Sanofi
  The subject of the invention is benzofuran, benzothiophene, indole or indolizine compounds of general formula: ##STR1## in which: Het represents one of the groups: ##STR2## in which T,T' and T"represent particularly a group: ##STR3## R and R.sub.a, identical or different, represent X represent --O-- or --S-- Y represents a radical ##STR4## These compounds are useful as medecines particularly for the treatment of pathological syndroms of the cardio-vascular system.
  
  Patent expiration dates:
  
  
  • July 26, 2012
    
    ✓ 
    Patent use: REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Solid pharmaceutical composition containing benzofuran derivatives
  Patent 7,323,493
  Issued: January 29, 2008
  Inventor(s): Abramovici; Bernard & Gautier; Jean-Claude & Gromenil; Jean-Claude & Marrier; Jean-Marie
  Assignee(s): Sanofi-Aventis
  The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.
  
  Patent expiration dates:
  
  
  • June 19, 2018
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 1, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Multaq Consumer Information (Drugs.com)
• Multaq Consumer Information (Wolters Kluwer)
• Multaq Consumer Information (Cerner Multum)
• Multaq Advanced Consumer Information (Micromedex)
• Multaq AHFS DI Monographs (ASHP)
• Dronedarone Consumer Information (Wolters Kluwer)
• Dronedarone Consumer Information (Cerner Multum)
• Dronedarone Advanced Consumer Information (Micromedex)
• Dronedarone Hydrochloride AHFS DI Monographs (ASHP)